![]() While approved therapies exist for those patient populations, those therapies won’t work for women diagnosed with triple negative breast cancer or ovarian cancer with BRCAness-a defect in the DNA repair process that imitates BRCA mutations, even though the gene is intact. ![]() Patients who inherit mutations in the BRCA1 or BRCA2 genes are at higher risk for breast and ovarian cancers. Nephew and Miller, both researchers at the Vera Bradley Foundation Center for Breast Cancer Research at the IU Simon Comprehensive Cancer Center, will collaborate with project co-investigator Feyruz Rassool, PhD, of the University of Maryland School of Medicine. The project at Indiana University will investigate the impact of epigenetic therapy on cancers driven by BRCAness, a major cancer-related vulnerability. The SPORE grant was awarded to The Coriell Institute for Medical Research (Camden, NJ) and Van Andel Institute (Grand Rapids, MI) and includes three research projects focusing on epigenetic therapy, which aims to treat cancer by correcting abnormal gene expression. Kathy Miller, MD and Ken Nephew, PhD are among nearly 20 scientists at six institutions who will work to improve epigenetic therapies for cancer with the five-year, estimated $12.4 million grant. ![]() INDIANAPOLIS-Two Indiana University Melvin and Bren Simon Comprehensive Cancer Center researchers are now part of a prestigious Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute. IU research could lead to new treatment options for breast and ovarian cancer patients
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |